⚔️ CROX vs EEFT vs NVO vs PDD

📋 Executive Summary

Seven legendary investors — Buffett, Munger, Kantesaria, Tepper, Vinall, Pabrai, and Prasad — debated which of four deeply discounted stocks they'd own for the next decade: foam clog maker Crocs (CROX) at under 5× earnings, global payments operator Euronet Worldwide (EEFT) at under 10×, GLP-1 pharmaceutical giant Novo Nordisk (NVO) at 10×, and Chinese e-commerce platform PDD Holdings (PDD) at under 10×. The central tension: do you buy biological inevitability at a fair price, or a cash machine at a liquidation price and bet the brand survives?

• 🏆 Winner: Novo Nordisk (NVO) — 3 votes (Buffett, Vinall, Prasad). Patients who stop GLP-1 therapy regain two-thirds of lost weight within a year — biological lock-in more durable than any contract, serving a population that is 98% untreated, at a price that implies only 6% growth.

• 🥈 Runner-up: Crocs (CROX) — 2 votes (Munger, Pabrai). The market implies Crocs' earnings will decline 2% annually for a decade — the most pessimistic pricing of any stock in the group — while the brand grew 11% internationally in 2025 and management retired 10% of shares outstanding.

• ⚠️ Dividing risk: Whether Crocs is becoming a functional habit (like Coca-Cola) or remains a fashion cycle (like Harley-Davidson) — the brand collapsed once before, and current 27% ROIC sits at historical peak.

• 💡 Surprising insight: Kantesaria, who built the strongest intellectual case for Novo Nordisk's biological moat, voted against it — his blanket exclusion of healthcare forced him to pick Euronet instead, illustrating how investment frameworks can override conviction.

• 🔢 Most decisive metric: NVO's 43% ROIC reinvesting into a market with sub-2% penetration — every retained dollar compounds at rates unavailable to any other business on the table.

The debate split along philosophical lines: investors who trust price as the ultimate margin of safety chose Crocs' extreme discount, while those who trust business durability chose Novo Nordisk's biological lock-in. As Buffett concluded: "The best investment isn't always the cheapest — it's the one you can hold without watching."

PART 1: THE CONTENDERS

Buffett: "Let me frame what we're looking at, because this is an unusual lineup. Crocs makes foam clogs that cost fifteen dollars to produce and sell for fifty-five — a simple consumer product with franchise-like margins. Euronet operates the plumbing of global payments: ATMs, remittances, and digital content distribution across forty countries. Novo Nordisk sells weekly injections that patients cannot stop taking without measurable physical deterioration. And PDD runs a digital bazaar where Chinese factories sell directly to 900 million consumers, cutting out middlemen who typically extract the majority of the value chain."

¹NVO FCF converted from DKK ~40B at current exchange rates; depressed by massive CapEx cycle. ²PDD FCF converted from RMB ~121B. All other figures in USD.

"Three of these sport ROIC north of twenty percent, and every one trades at or below ten times earnings. That almost never happens simultaneously. The question isn't whether they're cheap — they obviously are. The question is which cheapness is warranted and which is a gift. Charlie, you usually start by asking what can go wrong."

Munger: "What jumps out is that these four businesses face entirely different extinction threats, and the probabilities aren't remotely equal. Crocs dies if teenagers decide foam is uncool — and that's not hypothetical, because it happened in 2012 when ROIC collapsed from 23% to 2% in a single year. Euronet dies if the EU regulates away ATM foreign-exchange spreads while Wise steals the remittance corridor. Novo Nordisk dies if Lilly's tirzepatide proves permanently superior and steals the prescribing relationship. PDD dies if Beijing extracts value from the platform or Washington eliminates the de minimis exemption. The one that I keep coming back to is Novo, because the threat there — competitive share loss within a duopoly — is the least existential. Even if Novo becomes number two, a duopoly serving 890 million eligible patients is still an extraordinary business. But before I get seduced by the obvious, I want to hear whether anyone thinks the fashion risk at Crocs is genuinely priced in at under five times earnings."

PART 2: BUSINESS QUALITY & MOATS

Kantesaria: "Charlie, before we discuss what's priced in, I want to establish what kind of businesses we're actually looking at, because my framework is binary: either a business sits at a mandatory checkpoint where economic activity cannot occur without paying its toll, or it doesn't. Novo Nordisk comes closest to that test — a patient who discontinues semaglutide regains roughly two-thirds of their lost weight within twelve months, which is physiological lock-in more powerful than any contract. But I want to be precise about a distinction the bulls keep glossing over: that biology locks patients into the drug class, not into Novo specifically. A doctor can switch a patient from Ozempic to Mounjaro with a new prescription and zero biological penalty. Crocs has zero mandatory characteristics; nobody wakes up compelled to buy foam clogs. Euronet has zero; tourists find another ATM, workers send money through Wise. PDD has zero; Chinese consumers shop across Alibaba, JD, and Douyin without friction. I admire Novo's business enormously, but I won't own a pharmaceutical company — my exclusion of healthcare is absolute, regardless of quality. So the question for me becomes: which of the remaining three comes closest to structural inevitability?"

Tepper: "Dev, I appreciate the intellectual framework, but it misses what actually makes money in markets — the gap between perception and reality. I don't need mandatory checkpoints; I need mispricing. And before we go deeper on moats, let me point out the elephant in the room: PDD has $58 billion in cash sitting on a $145 billion market cap. That means I'm buying the operating business for roughly $88 billion — less than six times last year's free cash flow. Li Lu and Duan Yongping are accumulating this stock right now, and these are people who understand Chinese consumer behavior in a way that Western institutions simply cannot. When the smartest specialists are buying what consensus is selling, that reflexive gap is where I make money."

Pabrai: "David, I respect the China thesis, but the math kills it for my framework. PDD at $145 billion needs to triple to $435 billion for my required three-to-one upside — larger than Alibaba ever reached. The stock I keep circling is Crocs, and I want to challenge the doom narrative directly. Everyone keeps citing the 2012 collapse, but the company that exists today is structurally different. Management outsourced all manufacturing, eliminated owned retail stores, built the Jibbitz personalization ecosystem that turns clogs into a self-expression platform, and created a collaboration machine — McDonald's, Bad Bunny, Balenciaga — that generates cultural relevance without traditional advertising spend. The historical parallel that matters isn't Harley-Davidson, which Charlie raised. It's Nike after the Air Jordan pivot in 1985. Nike was a functional running shoe company that transformed into a cultural brand through athlete partnerships and limited releases. Forty years later, that playbook still works. Crocs is running the same playbook with Jibbitz and collaborations."

Prasad: "Mohnish, that Nike parallel actually proves the opposite of what you intend. Nike survived four decades because it operates in athletic footwear — a category with genuine functional necessity. People need running shoes and basketball shoes regardless of fashion trends. Crocs operates in casual clogs, where the only functional claim is comfort, and comfort is trivially replicable. On Running could launch a foam clog tomorrow. The evolutionary question I keep asking is whether the environment Crocs inhabits is stable or volatile. Payroll tax rules change once a year. Semiconductor lithography evolves on multi-year cycles. But fashion sentiment can shift in a single TikTok trend cycle. Novo Nordisk has manufactured biological therapies since 1923 — over a century of continuous operation through world wars, patent cliffs, and complete therapeutic pivots. That's an organism adapted to its environment. Crocs nearly went extinct in 2013 and required a full management overhaul to survive. That's an organism that got lucky."

Buffett: "Pulak, you're making a strong case for Novo's durability, but let me push back on the Crocs dismissal with something concrete. The brand sold 1.5 billion pairs over twenty years and commands 60-70% market share in a clog category it essentially created. International sales grew 11% in 2025, with China up 30% and still representing only 8% of brand revenue. When I see a product expanding into markets where it's still novel — nurses in Shanghai, gardeners in Berlin, parents in São Paulo — that looks more like Coca-Cola entering new countries in the 1950s than a fashion fad peaking. But I genuinely don't know which identity wins: the functional utility product that people reach for without thinking, or the fashion statement that depends on cultural relevance. And that uncertainty is exactly why I can't put it in my predictability bucket."

Vinall: "Warren, that uncertainty is the crux of this entire debate, and it connects to something I've been thinking about with my moat framework. I rank moats by customer alignment — the best moats are ones where the customer benefits from the company's dominance, not ones where the customer is trapped. Novo Nordisk's moat is the biological equivalent of what I call the 'cost savings' moat: the patient genuinely benefits from continued therapy, and the company benefits from continued prescriptions. The interests are aligned. Crocs' moat, by contrast, is purely brand-based — and brand moats rank among the least reliable because what confers status changes over time. But I want to bring Euronet into this conversation, because nobody's seriously challenged its competitive position. The ATM business earns its fattest margins from dynamic currency conversion — charging tourists a 5-8% foreign exchange spread when they withdraw cash in an unfamiliar country. That's not a moat built on customer value; it's a moat built on customer confusion. And the EU has been scrutinizing those spreads for years."

Munger: "Robert makes an important distinction about moat alignment, and it reminds me of a historical parallel that's been nagging at me. Novo Nordisk in 2026 looks remarkably like Pfizer in 1999 — dominant franchise, seemingly permanent moat, and a stock price that assumed perpetual growth. Pfizer's patent cliff arrived with Lipitor's expiration, and the stock went nowhere for fifteen years. The critical question is whether GLP-1 therapy is structurally different from a patented pill. And I think it is, for one reason: when a Lipitor patient switched to generic atorvastatin, they got identical results at lower cost. When a GLP-1 patient tries to stop therapy entirely, they regain the weight. The switching dynamic is fundamentally different — you're not switching products, you're switching between treatment and no treatment. That's why the Pfizer analogy breaks down, even though it looks similar on the surface."

PART 3: FINANCIALS & TRACK RECORD

Kantesaria: "Charlie's Pfizer distinction is exactly right, and it matters enormously for the compounding math. Novo Nordisk earns forty-three cents of after-tax profit on every dollar of invested capital. To make that concrete: if management reinvests half of earnings at that return, the arithmetic alone drives over 20% organic earnings growth — before any share count reduction. I'm deliberately using our standardized 12% historical growth rate for projections, which is conservative relative to what the reinvestment math implies, but it keeps the comparison honest across all four stocks. Starting from $3.67 in EPS, twelve percent compounded over a decade delivers roughly $11.40. A chronic-therapy duopoly with biological lock-in deserves a premium exit multiple — I'd argue 20× is reasonable for a business this durable, which gets you to roughly $228 per share. That's over six times your money from today's $36.53, approximately twenty percent annualized. Now here's the second-order effect that matters: Novo spent DKK 180 billion on manufacturing capacity over 2023-2025, which is temporarily depressing free cash flow. But that capacity is built to serve ten times the current patient base. As utilization rises, margins should expand and FCF should inflect sharply — which means the base case may actually understate the compounding potential."

Munger: "Dev's math on Novo is compelling, but let me walk through what Crocs looks like at this entry price, because the numbers are striking for different reasons. At $75.78, I'm paying under five times for a business that generated $659 million in free cash flow last year — about $15 per share on roughly 52 million diluted shares. Using the same 12% historical growth rate over ten years, EPS reaches approximately $50. Even at a depressed 10× exit multiple, which assumes the market never fully trusts the brand, that's about $500 per share — roughly 6.6 times your money, or 21% annualized. What makes the financial profile unusual is the buyback machine: management retired 10% of shares outstanding in 2025, purchasing $577 million worth at trough prices. Share count has declined from 75 million in 2015 to 52 million today. That's real per-share value creation that doesn't depend on the brand staying fashionable."

Pabrai: "Charlie, let me build on your numbers with the asymmetry math, because the bear case is what I care about most. If the brand fades and HEYDUDE keeps declining, operating margin compresses to 18% — still above the footwear industry's 10-15% norm. In that scenario, normalized EPS drops to roughly $10, and at a distressed 6× multiple you get $60 — only 20% below today's price. That's my downside. The upside case: China grows from 8% to 20% of sales, HEYDUDE either stabilizes or gets divested, and ROIC stays above 20%. Then $50 EPS at 12-15× produces $600-750, call it eight to ten times my money. Downside twenty percent, upside eight to ten times — that's the asymmetric setup I spend my career looking for."

Vinall: "Mohnish, I want to challenge one critical assumption. You're treating the 27% ROIC as a sustainable baseline, but the trajectory tells a different story. Operating margins have compressed four consecutive years — from 29.5% in 2021 to 22.3% in 2025. And the 2012-2013 collapse took ROIC from 23% to 2% in a single year, which means the mid-cycle ROIC for this business is probably 15-18%, not 27%. Contrast that with Novo's growth quality: the obesity franchise went from DKK 6 billion to DKK 82 billion in six years, almost entirely organic. Wegovy launched in 35 new countries with 134% international sales growth last year. No acquisitions driving growth, no financial engineering — just a single molecule expanding into new populations and geographies. That's the highest-quality growth among these four businesses."

Tepper: "Robert, you're right about Novo's growth quality, but let me put PDD's financial engine on the table because it's genuinely extraordinary and nobody's engaged with it. This platform requires 0.24% of revenue in capital expenditure — essentially nothing. Revenue grew from zero to $57 billion in eight years. Now here's the second-order chain: PDD launched an RMB 100 billion merchant support program that the market reads as permanent margin destruction. But think one step further. Those subsidies include logistics support, advertising credits, and consumer traffic allocation. The merchant who accepts all three becomes operationally dependent on PDD's ecosystem. The first-order effect is margin compression from 27.5% to 22.4%. The second-order effect is ecosystem entrenchment that makes those margins recoverable once the competitive battle with Douyin and Kuaishou stabilizes. The question is whether management is investing or capitulating."

Prasad: "David, that's a hopeful interpretation, but it contradicts what management tells us directly. The Co-CEO said on the earnings call — and I'm quoting — 'our quarterly profitability will fluctuate and is inherently unpredictable.' When the people who understand the business far better than any of us explicitly warn shareholders to temper expectations, I pay attention. And here's the third second-order chain nobody's mentioned: if Beijing cracks down on platform economics again — as they did with Alibaba in 2021, capping commissions and imposing 'common prosperity' requirements — PDD's 24% ROIC compresses toward single digits regardless of competitive positioning. The regulatory risk isn't hypothetical; it has recent precedent."

Kantesaria: "Pulak raises a critical point. Let me bring Euronet back into the financial discussion because its capital allocation reveals both strengths and risks. Euronet repurchased $1.6 billion in shares over six years — disciplined commitment from a $3 billion company, and it amplified FCF per share growth to 17% versus 10% revenue growth. But the cash flow quality concerns me deeply. Operating cash flow dropped 37% from $733 million to $462 million while the business supposedly grew. Accounts receivable ballooned to $2.24 billion — 53% of trailing revenue. Most alarming is the settlement liquidity architecture: Euronet cycled $8 billion in gross debt issuance and repayment in 2024 on a $3 billion market cap. That daily borrowing-and-repaying mechanism is invisible in net debt analysis but represents catastrophic tail risk if settlement timing mismatches or counterparty failures ever disrupt the cycle. Starting from $7.00 EPS at 12% growth, ten years gets you roughly $21.74. At a 12× exit for a payment infrastructure business, that's $261 — about 3.9× your money, or 14.6% annualized. Adequate returns, but the settlement risk makes me uncomfortable."

PART 4: VALUATION & RETURN COMPARISON

Buffett: "Let me consolidate the math everyone's walked through, because the comparison reveals something important about what the market expects from each business. All four share the same 12% historical growth rate, which makes the projections unusually clean."

*Implied growth: the annual EPS growth rate baked into today's price assuming a 15× terminal multiple and 10% required return over 10 years.

"The implied growth row is the most important line in this table. The market is pricing Crocs for earnings decline — roughly negative two percent annually for a decade — while Euronet, NVO, and PDD are all priced for five to six percent growth. Every one of these companies has grown at double-digit rates historically. The gap between what's priced in and what's likely is where opportunity lives — or where the market knows something we don't."

Assumes exit multiples unchanged from base case, dividends excluded, 10-year horizon.

Munger: "Warren, the implied growth numbers are devastating for the PDD thesis. Five percent implied growth sounds pessimistic until you realize the business just decelerated from 59% to 9% in a single year. The market isn't being irrational about PDD; it's correctly reading a decelerating business with dual regulatory exposure from Washington and Beijing. Crocs is where the market is genuinely wrong. Negative two percent implied growth means the market expects the brand to slowly die — but China grew 30% and represents only 8% of sales, international grew 11%, and management just retired a tenth of shares outstanding. The gap between negative-two-percent expectations and the likely positive-single-digit reality is enormous."

Kantesaria: "Charlie, the implied growth analysis confirms where I'd put new capital if I could override my healthcare exclusion: six percent implied growth for Novo Nordisk is absurd for a company with 134% international Wegovy growth and a manufacturing build-out designed for ten times the current patient base. But I can't own pharma, so let me make the risk-adjusted case for Euronet. At 9.5× earnings, the market is pricing in modest 5% growth — roughly half the historical rate. If the EFT merchant acquiring business continues growing EBITDA at 32% as it did in 2024, and Dandelion wholesale settlement gains traction with Citi, HSBC, and Commonwealth Bank already onboard, the actual growth rate could surprise meaningfully above that 5% baseline. The exit multiple of 12× is conservative for a payment infrastructure business transitioning from asset-heavy ATMs to software-driven processing."

Pabrai: "Dev, your exit multiple argument on Novo works both ways. If Crocs deserves 12× instead of 10× — and a business with 25% operating margins arguably does — the annualized return jumps above 24%. The beauty of buying at under five times is that any multiple expansion is pure upside. Novo needs its 20× exit just to match Crocs' returns. The scenario table makes it concrete: in the bear case, Crocs and Novo produce nearly identical outcomes — $378,000 versus $360,000. But Crocs' bear case assumes the brand fades, while Novo's bear case assumes mere growth deceleration. I'd argue Crocs' bear case is the more extreme assumption, which means its expected value is higher."

Tepper: "Mohnish, you're right about the bear-case symmetry, but you're ignoring the tail risk distribution. Crocs' bear case could easily be worse than 6% growth — the 2012 collapse wasn't gradual, it was sudden. Fashion brands don't fade gently; they cliff. PDD's bear case, by contrast, has a floor provided by that massive cash balance. Even if Temu goes to zero and the domestic business halves, you've still got $58 billion in cash against a $145 billion market cap. The asymmetry isn't in the base case projections — it's in what happens when things go wrong."

PART 5: RISKS, PRE-MORTEM & SIGNPOSTS

Buffett: "Before we vote, let's assume each of these stocks lost half its value by 2029. Write the obituary — what specifically went wrong?"

Munger: "I'll take PDD. It's 2029 and the stock is at $48. Washington eliminated the de minimis exemption in late 2026, adding an effective 25% tariff on every Temu package entering the United States. Simultaneously, Beijing launched a 'common prosperity' review capping platform take rates at 3%. Caught between two hostile governments, operating margins compressed to 8%, and Western institutional investors capitulated en masse."

Vinall: "Crocs' obituary. It's 2029 and the stock is at $38. The HEYDUDE brand consumed another $400 million in restructuring costs while revenue declined to $300 million — less than a third of its $2 billion acquisition price. Meanwhile, On Running launched a foam clog at $40 that became the new healthcare worker obsession, and North American decline accelerated from 7% to 15% annually. Management stubbornly refused to divest HEYDUDE, and the combined drag proved that peak ROIC was exactly that — a peak."

Kantesaria: "Novo Nordisk's obituary. It's 2029 and the stock is at $18. CagriSema's pivotal trials showed only marginal superiority over tirzepatide, and Novo permanently lost the innovation leadership narrative. Generic semaglutide launched in India and Brazil, collapsing international pricing in the highest-growth markets. The DKK 180 billion manufacturing build-out became stranded capacity as patients shifted to Lilly's next-generation triple-agonist."

Prasad: "Euronet's obituary. It's 2029 and the stock is at $33. The EU passed comprehensive DCC transparency regulations in 2027, mandating real-time FX rate disclosure at every ATM — compressing Euronet's 5-8% spreads to 1-2% overnight. Wise crossed $200 billion in annual transfer volume, gutting Ria's margins. Then the settlement liquidity architecture experienced a two-day disruption during a European banking stress event, triggering a credit downgrade and a twenty-percent single-day stock decline."

Tepper: "Those pre-mortems are well constructed, but they all focus on business-specific threats. Let me name the risk that doesn't appear in any financial model: management succession. Novo just lost two senior commercial leaders during the most critical product launch in company history, replacing them with executives who have zero institutional experience. Crocs' turnaround was driven by a specific team — if they leave, the collaboration strategy unwinds. PDD's entire culture flows from Colin Huang, who stepped back from daily operations. Single-point-of-failure leadership is the risk that never shows up until it's too late."

Buffett: "Good. Now — the specific conditions that would make each of us change our minds."

Pabrai: "My signpost: If Crocs' North America brand revenue declines exceed 12% for two consecutive quarters while international growth decelerates below 10%, I'd switch to Euronet. That combination would mean the brand is dying globally, not just maturing in one market."

Kantesaria: "My signpost: If Novo's ROIC falls below 33% for two consecutive quarters — indicating the manufacturing build-out is diluting returns without proportional revenue — the high-return reinvestment thesis collapses, and I'd need to reassess entirely."

Vinall: "My signpost: If Novo's U.S. GLP-1 volume share falls below 45% while CagriSema Phase 3 data shows less than 25% weight loss, I'd switch to Crocs. That combination would mean Novo has permanently lost the molecule arms race."

Prasad: "My signpost: If PDD's operating margin stabilizes above 25% for three consecutive quarters while ROIC rebounds above 30%, I'd reconsider. That would prove the merchant subsidies created genuine ecosystem value rather than permanent margin destruction."

PART 6: INVESTOR PICKS

🦅 Buffett's Pick — Novo Nordisk A/S (NVO): "Among these four, Novo Nordisk is the only business where I can predict the earnings in 2035 without heroic assumptions. People will still be obese, the therapy will still work, and patients who stop will still regain the weight — that's biology, not fashion or geopolitics. I generally avoid pharmaceutical companies, but this isn't a patent-cliff treadmill; it's a chronic therapy serving a population that is overwhelmingly untreated. At ten times earnings with the highest ROIC on this table, the market is pricing a wonderful business as though it's facing obsolescence. I've learned over sixty years that certainty of outcome matters more than depth of discount — and no other stock on this table offers remotely comparable certainty."

🦉 Munger's Pick — Crocs Inc (CROX): "I'm going to disagree with my partner, which I've done profitably before. The implied growth analysis tells me the market is pricing Crocs for brand extinction, and I don't need to predict whether foam clogs will be cool in 2035 to know that extinction pricing is wrong. What I need to assess is whether the current free cash flow — about $15 per share — is a reasonable purchase at $76. The answer is obviously yes. If the brand fades gradually, the buyback machine still compounds my per-share ownership at trough prices, delivering double-digit returns. If it holds, I make several multiples. When the market offers you an adequate business at a liquidation price, the fashion risk becomes a feature — it's the reason the price is this low."

🎯 Kantesaria's Pick — Euronet Worldwide Inc (EEFT): "I built the strongest case for Novo's biological moat in this debate, and I believe every word of it — but I won't own pharmaceutical companies, and that exclusion isn't negotiable regardless of quality. Among the remaining three, Euronet comes closest to my framework because its payment infrastructure creates genuine supply-side barriers: banking licenses in forty countries, compliance teams in dozens of regulatory regimes, and a merchant acquiring business whose EBITDA grew 32% in 2024. The FCF per share compounding at 17% annually, powered by disciplined buybacks from a management team that has allocated $1.6 billion over six years, is the quiet value creation I respect. The settlement liquidity risk is real, but at 9.5× earnings I'm compensated for it."

🦁 Tepper's Pick — PDD Holdings Inc (PDD): "The setup here is classic reflexive selling — Western institutions dumping a Chinese asset because the narrative says 'uninvestable,' creating a price that embeds zero value for Temu and assumes permanent domestic impairment. After backing out the massive cash balance, I'm effectively paying less than six times operating free cash flow for a platform business that requires almost nothing in capital expenditure. If Beijing's regulatory stance moderates and the de minimis exemption survives in any form, this re-rates violently. I don't need PDD to be the best business on this table — I need it to be the most mispriced, and the gap between sentiment and fundamentals here is the widest I see."

📚 Vinall's Pick — Novo Nordisk A/S (NVO): "I own Novo Nordisk, and at $36.53 it's cheaper than any price I've ever paid. The competitive concerns about Lilly are real — I raised them myself — but as I argued earlier, being second in a biological duopoly whose addressable market is 98% untreated is still an extraordinary position. What seals it for me is the growth quality: purely organic, driven by clinical efficacy expanding into new geographies and patient populations, with no acquisitions or financial engineering required. The manufacturing CapEx cycle will normalize over the next three years, and when it does, free cash flow should inflect dramatically, justifying a price well above current levels. A century of institutional culture is a form of founder quality that passes my durability test."

🔥 Pabrai's Pick — Crocs Inc (CROX): "At $4.5 billion market cap, Crocs offers the most asymmetric payoff in this group. As I walked through earlier, the downside is roughly twenty percent if the brand fades, while the upside is eight to ten times if it holds and the multiple normalizes — a triple takes us to $13.5 billion, which is entirely plausible for a global footwear brand earning these returns on capital. The management team is doing my work for me, retiring shares at trough prices and mechanically increasing my ownership stake every quarter. I acknowledge the fashion risk, but at under five times earnings, I'm not paying for the brand to last forever — I'm paying for a few years of cash generation while the market figures out whether this is a habit or a phase."

🌿 Prasad's Pick — Novo Nordisk A/S (NVO): "My framework asks one question above all others: will this business exist and thrive in twenty years regardless of what happens in between? Novo Nordisk has manufactured biological therapies for over a century, adapting from insulin to GLP-1 without losing its identity. The chronic nature of this therapy transforms pharmaceutical economics from a patent-cliff treadmill into something closer to a consumer staple — patients refill prescriptions as reliably as they buy groceries. The slow-change nature of chronic disease biology makes this the most predictable earnings stream on the table. Fashion can disrupt on a TikTok timeline. Regulatory sentiment can shift with an election. Biology operates on evolutionary timescales — and that's the kind of environment where organisms like Novo survive and compound."

PART 7: THE VERDICT

Vote Count:

• NVO: 3 votes (Buffett, Vinall, Prasad)

• CROX: 2 votes (Munger, Pabrai)

• EEFT: 1 vote (Kantesaria)

• PDD: 1 vote (Tepper)

• Total: 7 votes ✓

🏆 Winner: Novo Nordisk A/S (NVO) — 3 votes

🥈 Runner-up: Crocs Inc (CROX) — 2 votes

⚠️ Dissent: Munger and Pabrai chose Crocs' extreme discount over Novo's biological certainty, arguing that at under 5× earnings, price itself provides the margin of safety that moat quality provides for Novo. Kantesaria picked Euronet as the closest to structural inevitability within his investable universe. Tepper chose PDD as the widest gap between sentiment and fundamentals.

The Swing Vote: Vinall was the decisive third vote for Novo Nordisk. His choice was genuinely torn — he acknowledged Crocs' extreme valuation repeatedly and his $5-50B market cap preference would normally steer him toward the smaller company. What tipped his decision was his core principle that a widening moat is more valuable than a wide moat: Novo's competitive position strengthens with every new patient enrolled, while Crocs' moat depends on cultural sentiment that can narrow without warning. If Crocs' North American revenue turns positive for two consecutive quarters, Vinall says he'd reconsider.

Conviction Spectrum: Buffett and Prasad were locked in from the opening — biological predictability aligned perfectly with both their frameworks, and neither seriously considered an alternative. Pabrai was equally certain in the opposite direction — the asymmetric math at under 5× was overwhelming regardless of fashion risk. Munger was the most conflicted voter, acknowledging his own framework normally excludes fashion businesses but finding the extinction-level pricing impossible to ignore. Tepper and Kantesaria were confident outliers, each choosing a stock nobody else would touch.

Scenario Sensitivity: If Crocs' China revenue exceeds 15% of total brand sales while North American comparable revenue turns positive for two consecutive quarters, the vote likely flips to 4-3 in Crocs' favor, as Vinall's widening-moat objection dissolves and the brand-durability thesis gains hard evidence.

The question we couldn't settle: Is Crocs a habit or a fashion? If it's becoming a functional habit — embedded in nursing, gardening, parenting, and travel the way Coca-Cola embedded itself in daily routines — then CROX at under 5× earnings is the most mispriced stock on this table and should have won unanimously. If it remains fundamentally a fashion product, then the 2012 collapse is a base rate that matters, and NVO's biological inevitability is worth paying a higher multiple. Watch Crocs brand North America same-store trends through Q3 2026: if they turn positive, the habit thesis gains real evidence. If they accelerate negative below -10%, the fashion cycle is repeating.

Buffett: "Every investor at this table found something genuinely compelling, and the three-two-one-one split tells you this wasn't easy. But notice what united the majority: we picked the business where we could close our eyes for ten years and sleep soundly. The best investment isn't always the cheapest — it's the one you can hold without watching."